BioMed Research International / 2021 / Article / Tab 1 / Research Article
Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications Table 1 Changes in differences between prices for the originator and biosimilar insulin glargine 100 IU/ml across Europe in recent years (based on local costs/DDD).
(a)
Albania Austria B & H Bulgaria Catalonia (Spain) % difference originator vs. biosimilar price Launch of the biosimilar Not applicable Not applicable No difference 4.7% 30.0% Latest difference Not applicable Not applicable 7.9% 5.7% Similar % price change over time (from 2014/2015 to 2020) Originator -32.0% No change -11.3% -10.8% -23.1% Biosimilar Not applicable Not applicable -17.1% -11.7% No change
(b)
Czech Republic Estonia Hungary Italy Latvia Lithuania % difference originator vs. biosimilar price Launch of the biosimilar 17.1% 16.4% 28.2% Not recorded Not applicable 12.3% Latest difference Similar 7.1% 1.6% 31.6% Not applicable Similar % price change over time (from 2014/2015 to 2020) Originator -25.5% -24.9% -21.2% 52.3% -14.4% -21.1% Biosimilar -7.7% Stable 1.2% Not recorded Not applicable -6.8%
(c)
Malta Norway Poland Scotland Slovenia Sweden % difference originator vs. biosimilar price Launch of the biosimilar Not applicable 12.1% 24.7% 18.1% 22.9% 13.6% Latest difference Not applicable 5.9% 0.2% 7.5% 9.9% 0.6% % price change over time (from 2014/2015 to 2020) Originator -61.3% -3.6% -31.1% -9.0% -20.3% -12.7% Biosimilar Not applicable 2.1% -6.5% No change No change -1.4%